Skip to content

Atripla takes a key step towards European approval

Financial worries predict poor adherence to anti-HIV therapy in US patients

Hypersensitivity reaction in patient taking Truvada with similar symptoms to abacavir allergy

Up to 40% of ART recipients in Africa have died or discontinued treatment within two years

Why are many US patients presenting later for HIV testing and care today than in 1990?

Good virological outcome in patients starting HIV therapy in the UK

Raltegravir receives accelerated approval from the FDA

Studies underway to find the best time to start anti-HIV therapy in those taking TB treatment

Sudden increases in viral load in first two years of infection could indicate superinfection